AU2001281140A1 - Anti-plasmodium compositions and methods of use - Google Patents

Anti-plasmodium compositions and methods of use

Info

Publication number
AU2001281140A1
AU2001281140A1 AU2001281140A AU8114001A AU2001281140A1 AU 2001281140 A1 AU2001281140 A1 AU 2001281140A1 AU 2001281140 A AU2001281140 A AU 2001281140A AU 8114001 A AU8114001 A AU 8114001A AU 2001281140 A1 AU2001281140 A1 AU 2001281140A1
Authority
AU
Australia
Prior art keywords
plasmodium
compositions
methods
plasmodium compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001281140A
Inventor
David L. Narum
Kim L. Sim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Casi Pharmaceuticals Inc
Original Assignee
Entremed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entremed Inc filed Critical Entremed Inc
Publication of AU2001281140A1 publication Critical patent/AU2001281140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
AU2001281140A 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use Abandoned AU2001281140A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22352500P 2000-08-07 2000-08-07
US60/223,525 2000-08-07
PCT/US2001/024725 WO2002011756A2 (en) 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use

Publications (1)

Publication Number Publication Date
AU2001281140A1 true AU2001281140A1 (en) 2002-02-18

Family

ID=22836887

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001281140A Abandoned AU2001281140A1 (en) 2000-08-07 2001-08-07 Anti-plasmodium compositions and methods of use

Country Status (3)

Country Link
US (2) US20020127241A1 (en)
AU (1) AU2001281140A1 (en)
WO (1) WO2002011756A2 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002338238A1 (en) * 2001-04-02 2002-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine
WO2006081308A2 (en) 2005-01-25 2006-08-03 The Johns Hopkins University Plasmodium diagnostic assay device
US8252293B2 (en) * 2006-09-14 2012-08-28 Nanyang Technological University Binding domain of Plasmodium reticulocyte binding proteins
US8703147B2 (en) * 2007-11-05 2014-04-22 The Walter And Eliza Hall Institute Of Medical Research Methods and compositions for treating and preventing malaria (2)
WO2010034183A1 (en) * 2008-09-26 2010-04-01 The University Of Hong Kong Human catechol-o-methyltransferase (comt) assay
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108117586A (en) 2010-08-10 2018-06-05 洛桑聚合联合学院 Erythrocyte binding therapeutic agent
CN103965312B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965339B (en) * 2013-01-28 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965318B (en) * 2013-01-28 2016-12-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965316B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965315B (en) * 2013-01-28 2016-12-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965317B (en) * 2013-01-28 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965319B (en) * 2013-01-28 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965328B (en) * 2013-01-29 2016-09-28 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965332B (en) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
CN103965330B (en) * 2013-01-29 2016-08-10 苏州偲聚生物材料有限公司 Polypeptide, the detection device comprising this polypeptide and detection kit
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG10202010936RA (en) 2014-02-21 2020-12-30 Ecole Polytecnique Fed De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3817837A (en) * 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US5993827A (en) * 1993-09-10 1999-11-30 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
EP0719333B1 (en) * 1993-09-10 2005-01-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES Binding domains from plasmodium vivax and plasmodium falciparum erythrocyte binding proteins
WO2000052056A2 (en) 1999-03-04 2000-09-08 Entremed, Inc. Anti-plasmodium compositions and methods of use
AU2002338238A1 (en) * 2001-04-02 2002-10-15 The Government Of The United States Of America, As Represented By The Secretary, Department Of Healt Plasmodium falciparum erythrocyte binding protein baebl for use as a vaccine

Also Published As

Publication number Publication date
US20020127241A1 (en) 2002-09-12
US7303751B2 (en) 2007-12-04
WO2002011756A2 (en) 2002-02-14
WO2002011756A3 (en) 2003-01-09
US20060153881A1 (en) 2006-07-13

Similar Documents

Publication Publication Date Title
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
AU2001241474A1 (en) Biosensor compositions and methods of use
AU2609901A (en) Antimicrobial compositions and methods of use
AU2001285020A1 (en) P97-active agent conjugates and their methods of use
AU7362301A (en) Bioadhesive compositions and methods of preparation and use
EP1283707A4 (en) Polymerizable compositions and methods of use
AU2002320058A1 (en) Magnetic-nanoparticle conjugates and methods of use
AU6118001A (en) Combination therapeutic compositions and methods of use
AU2002225954A1 (en) Dipeptidylpeptidases and methods of use
AU2002314466A1 (en) Withasol and methods of use
AU2001234437A1 (en) Deicing compositions and methods of use
AU2002327055A8 (en) Topical compositions and methods of application
AU2002216346A1 (en) Cabergoline pharmaceutical compositions and methods of use thereof
AU2002213346A1 (en) Osteopontin-coated surfaces and methods of use
IL157231A0 (en) Parasiticidal compositions and methods of use
AU2001280721A1 (en) Compositions of iodonium compounds and methods and uses thereof
AU2001293048A1 (en) Antiviral compositions and methods of use
AU2002252387A1 (en) Novel anti-inflammatory compositions and methods of use
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2001264863A1 (en) Preparation of fagopyritols and uses therefor
AU5179800A (en) Mycolactone and related compounds, compositions and methods of use
AU2001261496A1 (en) Luxo-sigma54 interactions and methods of use
AU2001265280A1 (en) Preparation of 2-hydroxy-5-oxoproline and analogs thereof
AU2002364911A1 (en) Dmt-tic di- and tri-peptidic derivatives and related compositions and methods of use
AU2001274022A1 (en) Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments